<i>"What would be left of me?"</i> Patient perspectives on the risks of obesity treatment: An innovative health initiative stratification of obesity phenotypes to optimise future obesity therapy (IMI2 SOPHIA) qualitative study.
<i>「我還剩下什麼?」</i> 病人對肥胖治療風險的看法:一項創新的健康倡議,對肥胖表現進行分層以優化未來肥胖療法 (IMI2 SOPHIA) 定性研究。
Obes Pillars 2024-09-13
Milestones in the journey towards addressing obesity; Past trials and triumphs, recent breakthroughs, and an exciting future in the era of emerging effective medical therapies and integration of effective medical therapies with metabolic surgery.
肥胖問題處理之旅中的里程碑:過去的試驗和勝利、最近的突破,以及在新興有效醫學療法時代和將有效醫學療法與代謝手術整合的令人振奮未來。
Metabolism 2023-10-16
Highway to the danger zone? A cautionary account that GLP-1 receptor agonists may be too effective for unmonitored weight loss.
GLP-1 受體激動劑可能對未受監控的體重減輕過於有效的警示。
Obes Rev 2024-04-22
Current perspectives in obesity management: unraveling the impact of different therapy approach in real life obesity care.
肥胖管理的當前觀點:揭示現實生活中不同治療方法對肥胖護理的影響。
J Transl Med 2024-06-06
GLP-1 agonists and risk of suicidal thoughts and behaviours: Confound by indication once again? A narrative review.
GLP-1 受體激動劑與自殺念頭和行為的風險:再次受到指示混淆的影響?一篇敘述性綜述。
Eur Neuropsychopharmacol 2024-07-28
Patient perspectives on incretin-based weight loss medications and relationship with demographic factors.
基於胰高血糖素樣肽的減重藥物的病人觀點及其與人口統計因素的關係。
Obes Sci Pract 2024-08-07